Trial reportClinical pharmacokinetics2017
Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide.
Trial report in Clinical pharmacokinetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01097148 (Peri -and Postoperative Drug Therapy Schedules for Morbidly Obese Patients), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Peri -and Postoperative Drug Therapy Schedules for Morbidly Obese Patients
Who cites it
23 citing papers in PubMed, 53 citations in OpenAlex.
- Morphine and hydromorphone pharmacokinetics in human volunteers: population-based modelling of interindividual and opioid-related variability.British journal of anaesthesia · 2025Trial
- Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover-design trial.British journal of clinical pharmacology · 2024Trial
- Comparison of the Onset of Action, Maintenance, and Recovery of Three Weight-based Dosing of Cisatracurium in Patients with Morbid Obesity in Laparoscopic Bariatric Surgery: A Randomized Clinical Trial.Iranian journal of medical sciences · 2023Trial
- ROUX-IN-Y GASTROJEJUNAL BYPASS: WHICH ANESTHETIC TECHNIQUE HAS BEST RESULTS?Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2021Trial
- Pharmacokinetics of Morphine and Morphine-6-Glucuronide During Postoperative Pain Therapy in Cardiac Surgery Patients.European journal of drug metabolism and pharmacokinetics · 2021Trial
- Population Pharmacokinetics of IV Lidocaine and its Metabolites in Adult Surgical Patients.Pharmaceutical research · 2025Article
- All You Need to Know About Allometric Scaling: An Integrative Review on the Theoretical Basis, Empirical Evidence, and Application in Human Pharmacology.Clinical pharmacokinetics · 2025Review
- Safety and efficacy of remifentanil in patients undergoing bariatric and metabolic surgeries - A systematic review.Indian journal of anaesthesia · 2025Article
- Pharmacokinetics of oral spironolactone in infants up to 2 years of age.European journal of clinical pharmacology · 2024Article
- Levothyroxine therapy, calculated deiodinases activity and basal metabolic rate in obese or nonobese patients after total thyroidectomy for differentiated thyroid cancer, results of a retrospective observational study.Endocrinology, diabetes & metabolism · 2023Observational
- Chemotherapy and Anticancer Drugs Adjustment in Obesity: A Narrative Review.Current medicinal chemistry · 2023Review
- Clinical Update on Patient-Controlled Analgesia for Acute Postoperative Pain.Pharmacy (Basel, Switzerland) · 2022Review
- Inflammasome activation as a link between obesity and thyroid disorders: Implications for an integrated clinical management.Frontiers in endocrinology · 2022Review
- Pharmacokinetic modeling of morphine and its glucuronides: Comparison of nebulization versus intravenous route in healthy volunteers.CPT: pharmacometrics & systems pharmacology · 2022Article
- OpiTrack: A Wearable-based Clinical Opioid Use Tracker with Temporal Convolutional Attention Networks.Proceedings of the ACM on interactive, mobile, wearable and ubiquitous technologies · 2021Article
- Physiologically-Based Pharmacokinetic Model of Morphine and Morphine-3-Glucuronide in Nonalcoholic Steatohepatitis.Clinical pharmacology and therapeutics · 2021Article
- Developmental Considerations for the Use of Naltrexone in Children and Adolescents.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Article
- Effects of Obstructive Sleep Apnea and Obesity on Morphine Pharmacokinetics in Children.Anesthesia and analgesia · 2020Article
- Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium.Critical care (London, England) · 2020Review
- Analgesic Effect of Morphine Added to Bupivacaine in Serratus Anterior Plane Block Following Modified Radical Mastectomy. Only a Local Effect? Randomized Clinical Trial.Journal of pain research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionObesity is associated with many pathophysiological changes that may result in altered drug metabolism. The aim of this study is to investigate the influence of obesity on the pharmacokinetics of morphine, morphine-3-glucuronide (M3G), and morphine-6-glucuronide (M6G) through a combined analysis in morbidly obese patients and non-obese healthy volunteers.
methodsIn this analysis, data from 20 morbidly obese patients [mean body mass index 49.9 kg/m
resultsIn morbidly obese patients, elimination clearance of M3G and M6G was decreased substantially compared with healthy volunteers (p < 0.001). Regarding glucuronidation, only a slight decrease in the formation of M6G and a delay in the formation of M3G was found (both p < 0.001). Obesity was also identified as a covariate for the peripheral volume of distribution of morphine (p < 0.001).
conclusionMetabolism of morphine is not altered in morbidly obese patients. However, decreased elimination of both M3G and M6G is evident, resulting in a substantial increase in exposure to these two metabolites. A rational explanation of this finding is that it results from alterations in membrane transporter function and/or expression in the liver. ClinicalTrials.gov identifier: NCT01097148.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.